CS275231B2 - Medicine bottle - Google Patents

Medicine bottle

Info

Publication number
CS275231B2
CS275231B2 CS895552A CS555289A CS275231B2 CS 275231 B2 CS275231 B2 CS 275231B2 CS 895552 A CS895552 A CS 895552A CS 555289 A CS555289 A CS 555289A CS 275231 B2 CS275231 B2 CS 275231B2
Authority
CS
Czechoslovakia
Prior art keywords
per
ointment base
antiphlogistics
medicine bottle
medcamentous
Prior art date
Application number
CS895552A
Other languages
English (en)
Inventor
Jitka Mudr Csc Cejkova
Jiri Ing Csc Vacik
Zdenek Prof Mudr Drsc Lojda
Original Assignee
Ustav Makormolekularni Chemie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ustav Makormolekularni Chemie filed Critical Ustav Makormolekularni Chemie
Priority to CS895552A priority Critical patent/CS275231B2/cs
Priority to CA002026166A priority patent/CA2026166A1/en
Priority to DE69030476T priority patent/DE69030476T2/de
Priority to AT90310516T priority patent/ATE151640T1/de
Priority to AU63170/90A priority patent/AU6317090A/en
Priority to US07/588,322 priority patent/US5244673A/en
Priority to EP90310516A priority patent/EP0420600B1/en
Publication of CS275231B2 publication Critical patent/CS275231B2/cs

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55Protease inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • A61K9/0051Ocular inserts, ocular implants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Centrifugal Separators (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
CS895552A 1989-09-29 1989-09-29 Medicine bottle CS275231B2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CS895552A CS275231B2 (en) 1989-09-29 1989-09-29 Medicine bottle
CA002026166A CA2026166A1 (en) 1989-09-29 1990-09-25 Medicamentous form
DE69030476T DE69030476T2 (de) 1989-09-29 1990-09-26 Verwendung von Protease-Inhibitoren als antiexudative, antiphlogistische und antimikrobielle Mittel
AT90310516T ATE151640T1 (de) 1989-09-29 1990-09-26 Verwendung von protease-inhibitoren als antiexudative, antiphlogistische und antimikrobielle mittel
AU63170/90A AU6317090A (en) 1989-09-29 1990-09-26 Medicamentous form
US07/588,322 US5244673A (en) 1989-09-29 1990-09-26 Medicamentous form for use as an ophthalmologic, otolaryngologic, or dermatologic drug
EP90310516A EP0420600B1 (en) 1989-09-29 1990-09-26 Use of protease inhibitors as antiexudative, antiphlogistic and antimicrobial agents

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CS895552A CS275231B2 (en) 1989-09-29 1989-09-29 Medicine bottle

Publications (1)

Publication Number Publication Date
CS275231B2 true CS275231B2 (en) 1992-02-19

Family

ID=5400638

Family Applications (1)

Application Number Title Priority Date Filing Date
CS895552A CS275231B2 (en) 1989-09-29 1989-09-29 Medicine bottle

Country Status (7)

Country Link
US (1) US5244673A (cs)
EP (1) EP0420600B1 (cs)
AT (1) ATE151640T1 (cs)
AU (1) AU6317090A (cs)
CA (1) CA2026166A1 (cs)
CS (1) CS275231B2 (cs)
DE (1) DE69030476T2 (cs)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2054180C1 (ru) * 1991-08-21 1996-02-10 Жирнов Олег Петрович (н/п) Способ лечения вирусных респираторных инфекций
ES2179038T3 (es) * 1991-09-13 2003-01-16 Pentapharm Ag Fraccion porteinica para el tratamiento cosmetico y dermatologico de la piel.
FI920206A0 (fi) * 1992-01-17 1992-01-17 Pekka Untamo Heino Medicinsk anvaendning, medicinskt foerfarande och preparat.
GB2271507A (en) * 1992-09-04 1994-04-20 Summit Technology Ireland Bv Compositions containing plasmin activity inhibitors
IL109705A (en) * 1993-06-17 1998-07-15 Allergan Inc Enzyme compositions and methods for contact lens cleaning
US5783532A (en) * 1993-06-17 1998-07-21 Allergan Enzyme compositions and methods for contact lens cleaning
AU7928294A (en) * 1993-10-06 1995-05-01 Allergan, Inc. Compositions and methods for inhibiting and reducing lysozyme deposition on hydrophilic contact lenses
US5688781A (en) * 1994-08-19 1997-11-18 Bristol-Myers Squibb Company Method for treating vascular leak syndrome
GB2318732A (en) 1996-11-01 1998-05-06 Johnson & Johnson Medical Wound healing compositions containing alpha-1-antitrypsin
WO1998051281A1 (en) * 1997-05-14 1998-11-19 Senju Pharmaceutical Co., Ltd. Aqueous suspension preparations with excellent redispersibility
US6914057B1 (en) 1998-09-28 2005-07-05 The Research Foundation Of State University Of New York Inhibitor of cataract formation
AU759372B2 (en) * 1998-09-28 2003-04-10 Research Foundation Of The State University Of New York, The A novel inhibitor of cataract formation
IL142037A0 (en) * 2001-03-15 2002-03-10 Agis Ind 1983 Ltd Pharmaceutical compositions containing a non-steroidal anti-inflammatory drug
KR100450864B1 (ko) * 2001-11-23 2004-10-01 한국과학기술연구원 Rna 표적 분자에 대해 특이성이 향상된네오마이신-클로람페니콜 헤테로 이합체 및 그의 제조방법
DE10227938B4 (de) * 2002-06-21 2006-07-20 Heraeus Kulzer Gmbh Pharmazeutische Zubereitung, Verfahren zu ihrer Herstellung sowie deren Verwendung
ATE439853T1 (de) * 2002-11-20 2009-09-15 Arriva Prometic Inc Zusammensetzung zur behandlung von ichthyosis unter verwendung von antitrypsin
EP1740168A2 (en) * 2004-04-21 2007-01-10 Advanced Ocular Systems Limited Antiprostaglandins for the treatment of ocular pathologies
US20070248646A1 (en) * 2006-02-16 2007-10-25 Ali Hafezi-Moghadam Use of azurocidin inhibitors in prevention and treatment of ocular vascular leakage
TW200812645A (en) * 2006-06-15 2008-03-16 Serenex Inc Tetracycline package formulations
FI20105572A0 (fi) 2010-05-24 2010-05-24 Prevab R Lcc Muokattu beeta-laktamaasi ja siihen liittyvät menetelmät ja käytöt
BR112016023360B1 (pt) 2014-04-17 2023-03-07 Synthetic Biologics, Inc Beta-lactamase e seu uso
AU2015308897B2 (en) 2014-08-28 2021-03-04 Theriva Biologics, Inc. E. coli-based production of beta-lactamase
US10105322B2 (en) 2014-10-08 2018-10-23 Synthetic Biologics, Inc. Beta-lactamase formulations and uses thereof
US9744221B2 (en) 2014-12-23 2017-08-29 Synthetic Biologics, Inc. Method and compositions for inhibiting or preventing adverse effects of oral antibiotics
JP6810697B2 (ja) 2015-02-23 2021-01-13 シンセティック・バイオロジクス・インコーポレイテッド 腸内マイクロバイオームの保護のために抗生物質と共に使用するカルバペネマーゼ
CA2978604C (en) 2015-03-06 2025-07-08 Synthetic Biologics Inc SAFE AND EFFECTIVE BETA-LACTAMASE DOSAGE FOR MICROBIOME PROTECTION
WO2017146603A1 (en) * 2016-02-24 2017-08-31 Arcasiu Nicolae Pharmaceutical composition for the treatment of burns, use, and method of treatment
WO2018075810A1 (en) * 2016-10-18 2018-04-26 Somahultion, Llc Dermatological compositions for providing nutrients to skin and methods thereof
US10328154B2 (en) * 2017-10-27 2019-06-25 BUFFERAD Illinois Inc. Topical compositions for improved delivery of active agents

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1390541A (en) * 1971-04-14 1975-04-16 Otsuka Kagaku Yakuhin Anti-inflammatory compositions
SE375007B (cs) * 1972-11-30 1975-04-07 Pharmacia Ab
FI854634A0 (fi) * 1985-11-22 1985-11-22 Labsystems Oy Foerfarande foer bestaemning av proteolytisk aktivitet.

Also Published As

Publication number Publication date
DE69030476T2 (de) 1997-11-27
US5244673A (en) 1993-09-14
EP0420600A2 (en) 1991-04-03
EP0420600B1 (en) 1997-04-16
DE69030476D1 (de) 1997-05-22
EP0420600A3 (en) 1992-11-19
CA2026166A1 (en) 1991-03-30
AU6317090A (en) 1991-04-11
ATE151640T1 (de) 1997-05-15

Similar Documents

Publication Publication Date Title
CS275231B2 (en) Medicine bottle
TW234691B (cs)
TW337488B (en) A carbohydrate glass matrix for the sustained release of a therapeutic agent
AU5094985A (en) Wound healing agents
AU3351293A (en) Piperidineacetic acid derivatives as inhibitors of fibrinogen-dependent blood platelet aggregation
GB2276819B (en) Aqueous wound treatment composition comprising a polysaccharide and hexylene glycol
AU3382995A (en) Combined preparation for the therapy of immunological diseases
CA2136331A1 (en) New pharmaceutical uses of krill enzymes
MY106271A (en) Cyclosporin ophthalmic compositions.
AU2689292A (en) Cyclohexaneacetic acid derivatives as inhibitors of fibrinogen-dependent blood platelet aggregation
AU5938398A (en) Pour-on formulations containing polymeric material, glycols and glycerides
GR3033728T3 (en) Tablets containing thioctic acid with a specified size.
CA2340734A1 (en) Optically active pyridyl-4h-1,2,4-oxadiazine derivative and its use in the treatment of vascular diseases
DE69015910D1 (de) Pharmazeutische Verwendung von Fettsäuren.
AU1944997A (en) Angiogenic inhibitor containing tissue factor pathway inhibitor
MY112593A (en) A storage stable water solution for infusion containing a thrombin inhibitor
CA2067374A1 (en) Osteogenesis promoter
AU2360592A (en) Polyacrylic acid based ophthalmic compositions
AU5187493A (en) Use of certain methanebisphosphonic acid derivatives in fracture healing
PL307051A1 (en) Ophthalmic agent for local administration containing (s)-thymol semihydrate
GB9505082D0 (en) Medicament
AU643696B2 (en) Use of iodopropargyl esters of a-amino acid derivatives as antimicrobial agents
AU7037591A (en) Stabilization of t-pa pro
HK8994A (en) Medicament for treatment of pregnancy-induced hypertension
WO1987003590A1 (fr) Medicament pour le traitement des maladies du foie

Legal Events

Date Code Title Description
IF00 In force as of 2000-06-30 in czech republic
MM4A Patent lapsed due to non-payment of fee

Effective date: 20010929